Z
Zhongzhen Guan
Researcher at Sun Yat-sen University
Publications - 13
Citations - 6023
Zhongzhen Guan is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Lung cancer & FOLFIRI. The author has an hindex of 8, co-authored 13 publications receiving 5273 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Yoon-Koo Kang,W. K. Kang,D. B. Shin,J. Chen,J. Xiong,J. Wang,Mikhail Lichinitser,Zhongzhen Guan,Rustem Khasanov,L. Zheng,M. Philco-Salas,T. Suarez,J. Santamaria,G. Forster,P. I. McCloud +14 more
TL;DR: XP showed significant noninferiority for PFS versus FP in the first-line treatment of AGC and can be considered an effective alternative to FP.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
Ann-Lii Cheng,Zhongzhen Guan,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Tsai Sheng Yang,Won Young Tak,Hongming Pan,Shiying Yu,Jianming Xu,Fang Fang,Jessie Zou,Giuseppe Lentini,D. Voliotis,Yoon-Koo Kang +15 more
TL;DR: Experimental analyses suggest that sorafenib is effective for patients from the AP region with advanced HCC, irrespective of baseline status, and the efficacy and safety profiles in the subpopulations described were comparable with those in the overall study population.
Journal ArticleDOI
[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].
Jinwan Wang,Yan Sun,Yong Yu Liu,Qitao Yu,Yiping Zhang,Kai Li,Yun-zhong Zhu,Qinghua Zhou,Mei Hou,Zhongzhen Guan,Weilian Li,Wu Zhuang,Donglin Wang,Houjie Liang,Fengzhan Qin,Huishan Lu,Xiaoqing Liu,Hong Sun,Yanjun Zhang,Jiejun Wang,Suxia Luo,Ruihe Yang,Yuanrong Tu,X. Wang,Shu-ping Song,Jingmin Zhou,Li-fen You,Jing Wang,Chen Yao +28 more
TL;DR: The addition of YH-16 to NP regimen results in significantly and clinically meaningful improvement in response rate, median time to tumor progression, and clinical benefit rate compared with NP alone in advanced NSCLC patients.
Journal ArticleDOI
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Ann-Lii Cheng,Gerardo H. Cornelio,Lin Shen,Timothy J. Price,Tsai Sheng Yang,Ik Joo Chung,Guang Hai Dai,Jen Kou Lin,Atul Sharma,Kun-Huei Yeh,Brigette B.Y. Ma,Adel Zaatar,Zhongzhen Guan,Nehal Masood,Vichien Srimuninnimit,Thomas Yau,Peter Gibbs,Xiuwen Wang,Dinesh Chandra Doval,Seung Taek Oh,Byoung Yong Shim,Charity Gorospe,Hwei Ming Wang,Ekaphop Sirachainan,Andrew Hill,Kwang Wook Suh,Frank Beier,Sudipto Chatterjee,Robert Lim +28 more
TL;DR: Efficacy results appeared similar for patients treated with FOLFOX and FOLFIRI, suggesting once‐every‐2‐weeks cetuximab is effective and tolerable as first‐line therapy and may represent an alternative to weekly administration.